Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Quick Stats
Apr 02, 202660.0
AI Score
BUY0.5
Volume Ratio
May 05, 2026
Next Earnings
12
+ve Days (30d)
18
-ve Days (30d)
RIGL Stock Summary
Last updated Apr 02, 2026
RIGL is currently trading at $27.53, positioned below its 200-day moving average of $33.02, suggesting bearish momentum. The stock has a 52-week range of $15.5 to $52.24.
Technical Analysis: The 50-day moving average stands at $31.6, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 43.341, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.278, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates RIGL at 60.0/100 with a BUY recommendation.
RIGL (Rigel Pharmaceuticals Inc. (New)) Indicators
Last updated Apr 02, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 43.341 |
| CMF (20) | -0.278 |
| ROC (10) | 5.479 |
| ADX (14) | 39.431 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -1.504 |
| AROONOSC (14) | 64.286 |
| WILLAMS %R (14) | -21.341 |
| MFI (14) | 54.348 |
RIGL Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
RIGL Price vs Max Options Open Interest
RIGL Max Change In Options Open Interest
RIGL Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
RIGL Daily Out of Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
RIGL Daily In the Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
RIGL Most Active Options by Volume(near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Rigel Pharmaceuticals Inc. (New) is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
RIGL Moving Averages Analysis
RIGL (Rigel Pharmaceuticals Inc. (New)) Simple Moving Averages
Moving Averages are last updated Apr 02, 2026
| Days | MA |
|---|---|
| 10 | 26.48 |
| 20 | 26.73 |
| 30 | 29.02 |
| 50 | 31.6 |
| 100 | 37.18 |
| 200 | 33.02 |
RIGL Fundamental Analysis
| P/E (Forward) | 5.8207 |
| P/E (Trailing) | 1.4117 |
| Market Cap ($) | 508.0 million |
| Earnings/Share ($) | 19.48 |
| Net Proft Margin (%) | 1.2472 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | 4.7993 |
| EPS Estimate Next Year ($) | 4.7962 |
| WallStreet Target Price ($) | 51.2 |
| Most Recent Quarter |
Rigel Pharmaceuticals is participating in investor conferences to attract large institutional investors, such as investment banks and asset managers. These conferences aim to build confidence with parties that can significantly impact the stock price and future financing. The global market for rheumatoid arthritis therapies is expected to grow to $41.1 billion by 2030, providing potential annual revenue for Rigel Pharmaceuticals from their collaboration with Eli Lilly. Hedge funds and private equity firms are actively seeking high-growth biotech companies like Rigel, which has potential blockbuster drugs. Pension funds, endowment funds, and mutual funds specialized in biotech and healthcare are also interested in investing in such companies.
Updated 2025-08-31 03:00:02